Model Medicines, Inc.
AI-designed small molecule therapeutics targeting novel biological mechanisms
- Sector
- Biotech
- Headquarters
- San Deigo, CA
- Founded
- 2019
- Latest Form D
- $5.1M, Oct 2026
- Total capital
- $22.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $22.5M
- 5 Form D · last Oct 2026
- 0 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 20 pending · first 2026
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$5.1M
- Private capital raisedForm D · SEC · 4th filing$3.3M
- Private capital raisedForm D · SEC · 3rd filing$14.8M
- Private capital raisedForm D · SEC · 2nd filing$950K
- Private capital raisedForm D · SEC · 1st filing$3.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Daniel HadersExecutive OfficerNamed in SEC Form D filings
- Kip QuackenbushExecutive Officer, DirectorNamed in SEC Form D filings
- Marlon EvansExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 21- PendingUse Of Pipendoxifene For Treating Infections Of Dna VirusesUSPTOApplication 19554554
- PendingCompounds, Compositions, And Methods Of Treating Rna Viral InfectionsUSPTOApplication 19543832
- PendingCompounds, Compositions, And Methods Of Treating Rna Viral InfectionsUSPTOApplication 19434767
Show all 21 patent records
- Use Of Pipendoxifene For Treating Infections Of Dna VirusesJul 16, 2026 · Application 19554554Pending
- Compounds, Compositions, And Methods Of Treating Rna Viral InfectionsJun 25, 2026 · Application 19543832Pending
- Compounds, Compositions, And Methods Of Treating Rna Viral InfectionsMay 7, 2026 · Application 19434767Pending
- Use Of Pipendoxifene For Treating Infections Of Dna VirusesApr 16, 2026 · Application 19419109Pending
- Methods And Compositions For Treating Rna Viral InfectionsFeb 17, 2026 · US 12,551,475Granted
- Use Of Pipendoxifene To Treat SARS-COV-2 InfectionJan 23, 2025 · Application 18712214Pending
- Rdrp THUMB-1 As A Novel Broad-spectrum Antiviral Family Of TargetsApplication 63743555Pending
- Rdrp THUMB-1 As A Novel Broad-spectrum Antiviral Family Of TargetsApplication 63682664Pending
- Rdrp THUMB-1 As A Novel Broad-spectrum Antiviral Family Of TargetsApplication 63667563Pending
- Rdrp THUMB-1 As A Novel Broad-spectrum Antiviral Family Of TargetsApplication 63571351Pending
- Use Of Pipendoxifene To Treat SARS-COV-2 InfectionApplication PCTUS2022080573Pending
- Use Of Pipendoxifene To Treat SARS-COV-2 InfectionApplication 63350821Pending
- Use Of Pipendoxifene To Treat SARS-COV-2 InfectionApplication 63340363Pending
- Use Of Pipendoxifene To Treat SARS-COV-2 InfectionApplication 63284591Pending
- Methods And Compositions For Treating Rna Viral InfectionsApplication PCTUS2021035282Pending
- Methods And Compositions For Treating Rna Viral InfectionsApplication 63182507Pending
- Use Of Pipendoxifene For Treating Infections Of Dna VirusesApplication PCTUS2025036362Pending
- Use Of Pipendoxifene For Treating Co-infection Of Hbv And HcvApplication 63813739Pending
- Use Of Pipendoxifene For Treating Infections Of Dna VirusesApplication 63813736Pending
- Compounds, Compositions, And Methods Of Treating Rna Viral InfectionsApplication PCTUS2025021929Pending
- Rdrp THUMB-1 As A Novel Broad-spectrum Antiviral Family Of TargetsApplication 63745727Pending
Related companies, and why
- AZEVAN PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- CARAVEL BIO, INC.Similar federal contract value in Biotech · null in contracts
- Resilient Biotics, Inc.Similar federal contract value in Biotech · null in contracts
- Vetmab Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Mercury Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Accipiter Biosciences Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .